-
Something wrong with this record ?
Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling
AE. Yeoh, Z. Li, D. Dong, Y. Lu, N. Jiang, J. Trka, AM. Tan, HP. Lin, TC. Quah, H. Ariffin, L. Wong,
Language English Country England, Great Britain
Document type Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
29808917
DOI
10.1111/bjh.15252
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma blood genetics mortality MeSH
- Child MeSH
- Risk Assessment MeSH
- Infant MeSH
- Humans MeSH
- Survival Rate MeSH
- Predictive Value of Tests MeSH
- Child, Preschool MeSH
- Disease-Free Survival MeSH
- Recurrence MeSH
- Gene Expression Regulation, Leukemic * MeSH
- Gene Expression Profiling * MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Accurate risk assignment in childhood acute lymphoblastic leukaemia is essential to avoid under- or over-treatment. We hypothesized that time-series gene expression profiles (GEPs) of bone marrow samples during remission-induction therapy can measure the response and be used for relapse prediction. We computed the time-series changes from diagnosis to Day 8 of remission-induction, termed Effective Response Metric (ERM-D8) and tested its ability to predict relapse against contemporary risk assignment methods, including National Cancer Institutes (NCI) criteria, genetics and minimal residual disease (MRD). ERM-D8 was trained on a set of 131 patients and validated on an independent set of 79 patients. In the independent blinded test set, unfavourable ERM-D8 patients had >3-fold increased risk of relapse compared to favourable ERM-D8 (5-year cumulative incidence of relapse 38·1% vs. 10·6%; P = 2·5 × 10-3 ). ERM-D8 remained predictive of relapse [P = 0·05; Hazard ratio 4·09, 95% confidence interval (CI) 1·03-16·23] after adjusting for NCI criteria, genetics, Day 8 peripheral response and Day 33 MRD. ERM-D8 improved risk stratification in favourable genetics subgroups (P = 0·01) and Day 33 MRD positive patients (P = 1·7 × 10-3 ). We conclude that our novel metric - ERM-D8 - based on time-series GEP after 8 days of remission-induction therapy can independently predict relapse even after adjusting for NCI risk, genetics, Day 8 peripheral blood response and MRD.
2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Paediatrics KK Women's and Children's Hospital Singapore
School of Computing National University of Singapore Singapore
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012645
- 003
- CZ-PrNML
- 005
- 20190411093857.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.15252 $2 doi
- 035 __
- $a (PubMed)29808917
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Yeoh, Allen E-J $u Centre for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Viva-University Children's Cancer Centre, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore. Cancer Science Institute of Singapore, National University of Singapore, Singapore.
- 245 10
- $a Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling / $c AE. Yeoh, Z. Li, D. Dong, Y. Lu, N. Jiang, J. Trka, AM. Tan, HP. Lin, TC. Quah, H. Ariffin, L. Wong,
- 520 9_
- $a Accurate risk assignment in childhood acute lymphoblastic leukaemia is essential to avoid under- or over-treatment. We hypothesized that time-series gene expression profiles (GEPs) of bone marrow samples during remission-induction therapy can measure the response and be used for relapse prediction. We computed the time-series changes from diagnosis to Day 8 of remission-induction, termed Effective Response Metric (ERM-D8) and tested its ability to predict relapse against contemporary risk assignment methods, including National Cancer Institutes (NCI) criteria, genetics and minimal residual disease (MRD). ERM-D8 was trained on a set of 131 patients and validated on an independent set of 79 patients. In the independent blinded test set, unfavourable ERM-D8 patients had >3-fold increased risk of relapse compared to favourable ERM-D8 (5-year cumulative incidence of relapse 38·1% vs. 10·6%; P = 2·5 × 10-3 ). ERM-D8 remained predictive of relapse [P = 0·05; Hazard ratio 4·09, 95% confidence interval (CI) 1·03-16·23] after adjusting for NCI criteria, genetics, Day 8 peripheral response and Day 33 MRD. ERM-D8 improved risk stratification in favourable genetics subgroups (P = 0·01) and Day 33 MRD positive patients (P = 1·7 × 10-3 ). We conclude that our novel metric - ERM-D8 - based on time-series GEP after 8 days of remission-induction therapy can independently predict relapse even after adjusting for NCI risk, genetics, Day 8 peripheral blood response and MRD.
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a stanovení celkové genové exprese $7 D020869
- 650 12
- $a regulace genové exprese u leukemie $7 D015973
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a akutní lymfatická leukemie $x krev $x genetika $x mortalita $7 D054198
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Li, Zhenhua $u Centre for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Viva-University Children's Cancer Centre, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
- 700 1_
- $a Dong, Difeng $u School of Computing, National University of Singapore, Singapore.
- 700 1_
- $a Lu, Yi $u Centre for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Viva-University Children's Cancer Centre, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
- 700 1_
- $a Jiang, Nan $u Centre for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Viva-University Children's Cancer Centre, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
- 700 1_
- $a Trka, Jan $u 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Tan, Ah Moy $u Department of Paediatrics, KK Women's & Children's Hospital, Singapore.
- 700 1_
- $a Lin, Hai Peng $u Sime Darby Medical Centre, Subang Jaya, Malaysia.
- 700 1_
- $a Quah, Thuan Chong $u Centre for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Viva-University Children's Cancer Centre, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
- 700 1_
- $a Ariffin, Hany $u Faculty of Medicine, University of Malaya Cancer Research Institute, University of Malaya, Kuala Lumpur, Malaysia.
- 700 1_
- $a Wong, Limsoon $u School of Computing, National University of Singapore, Singapore.
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 181, č. 5 (2018), s. 653-663
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29808917 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411093915 $b ABA008
- 999 __
- $a ok $b bmc $g 1391955 $s 1050950
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 181 $c 5 $d 653-663 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20190405